Literature DB >> 26745749

Administration of the glial cell modulator, minocycline, in the nucleus accumbens attenuated the maintenance and reinstatement of morphine-seeking behavior.

Reza Arezoomandan1,1, Abbas Haghparast1,1.   

Abstract

Relapse to drug use is one of the most difficult clinical problems in treating addiction. Glial activation has been linked with the drug abuse, and the glia modulators such as minocycline can modulate the drug abuse effects. The aim of the present study was to determine whether minocycline could attenuate the maintenance and reinstatement of morphine. Conditioned place preference (CPP) was induced by subcutaneous injection of morphine (5 mg/kg) for 3 days. Following the acquisition of the CPP, the rats were given daily bilateral intra-NAc injections of either minocycline (1, 5, and 10 μg/0.5 μL) or saline (0.5 μL). The animals were tested for conditioning score 60 min after each injection. To induce the reinstatement, a priming dose of morphine (1 mg/kg) was injected 1 day after the final extinction day. The morphine-induced CPP lasted for 7 days after cessation of morphine treatment. Our data revealed that a priming dose of morphine could reinstate the extinguished morphine-induced CPP. Daily intra-accumbal injection of minocycline during the extinction period blocked the maintenance of morphine CPP and also attenuated the priming-induced reinstatement. Our findings indicated that minocycline could facilitate the extinction and attenuate the reinstatement of morphine. These results provided new evidence that minocycline might be considered as a promising therapeutic agent for the treatment of several symptoms associated with morphine abuse.

Entities:  

Keywords:  conditioned place preference; maintien de la dépendance à la morphine; minocycline; morphine maintenance; noyau accumbens; nucleus accumbens; préférence de place conditionnée; reinstatement; rétablissement

Mesh:

Substances:

Year:  2015        PMID: 26745749     DOI: 10.1139/cjpp-2015-0209

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  11 in total

Review 1.  The role of neuroimmune signaling in alcoholism.

Authors:  Fulton T Crews; Colleen J Lawrimore; T Jordan Walter; Leon G Coleman
Journal:  Neuropharmacology       Date:  2017-02-01       Impact factor: 5.250

2.  Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients.

Authors:  Caroline A Arout; Andrew J Waters; R Ross MacLean; Peggy Compton; Mehmet Sofuoglu
Journal:  Psychopharmacology (Berl)       Date:  2018-12-18       Impact factor: 4.530

Review 3.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

4.  Innate Immune Signaling and Alcohol Use Disorders.

Authors:  Leon G Coleman; Fulton T Crews
Journal:  Handb Exp Pharmacol       Date:  2018

5.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 6.  Neuroinflammatory Response in Reward-Associated Psychostimulants and Opioids: A Review.

Authors:  Saeideh Karimi-Haghighi; Sara Chavoshinezhad; Roghayeh Mozafari; Farshid Noorbakhsh; Afshin Borhani-Haghighi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2022-04-23       Impact factor: 5.046

Review 7.  Glial and neuroinflammatory targets for treating substance use disorders.

Authors:  Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

8.  Administration of the Glial Condition Medium in the Nucleus Accumbens Prolong Maintenance and Intensify Reinstatement of Morphine-Seeking Behavior.

Authors:  Reza Arezoomandan; Fariba Khodagholi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

Review 9.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

10.  Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users.

Authors:  S Mogali; P Askalsky; G Madera; J D Jones; S D Comer
Journal:  Pharmacol Biochem Behav       Date:  2021-07-21       Impact factor: 3.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.